Skip to main content

Table 1 Baseline data

From: Impact of HCV eradication following direct-acting antivirals on liver stiffness measurement: a prospective longitudinal study

Variables

 

Liver stiffness

  

p -value

 < 10 kPa ( n  = 54)

10–15 kPa ( n  = 17)

 > 15 kPa ( n  = 32)

Total ( n  = 103)

Age (year)

50.91 ± 11.11

57.12 ± 8.41

55.88 ± 7.98

54.63 ± 10.42

0.183

Gender (male)

23 (22.3%): 31 (30.1%)

9 (8.7%): 8 (7.8%)

18 (17.5%): 14 (13.6%)

50 (48.5%): 53 (51.5%)

0.436

BMI

26.17 ± 3.29

25.87 ± 3.44

26.79 ± 3.37

26.31 ± 3.33

0.595

Diabetes

9 (8.7%)

4 (3.9%)

8 (7.8%)

21 (20.4%)

0.612

AST (U/L)

45.91 ± 3.12

56.24 ± 4.64

61.49 ± 6.07

52.46 ± 4.30

0.111

ALT (U/L)

51.54 ± 4.31

48.77 ± 9.36

53.37 ± 4.57

51.65 ± 8.82

0.926

Albumin (g/dL)

4.14 ± 0.43

3.92 ± 0.58

3.54 ± 0.67

3.92 ± 0.60

0.0001*

Bilirubin (mg/dL)

0.72 ± 0.36

0.78 ± 0.29

0.99 ± 0.38

0.82 ± 0.37

0.004*

INR

1.06 ± 0.08

1.10 ± 0.17

1.24 ± 0.28

1.12 ± 0.19

0.0001*

PLTs/µL

222,259 ± 65,665

233,000 ± 64,647

164,406 ± 62,332

206,058 ± 69,864

0.0001*

AFP (ng/mL)

5.01 ± 3.20

5.03 ± 2.96

12.23 ± 2.86

7.26 ± 2.25

0.0001*

FIB-4

2.27 ± 1.41

3.41 ± 3.09

4.72 ± 2.30

3.21 ± 2.31

0.0001*

Liver stiffness (kPa)

6.26 ± 1.62

11.95 ± 1.15

29.99 ± 12.09

14.57 ± 12.57

0.0001*

  1. Numerical data are expressed as mean ± standard deviation, and categorical data are expressed as number (percentage)
  2. p-value: probability value. *Significant (p < 0.05)